Updated Estimates, Stock Movements, and Regulatory Approvals - Research Report on Quest Diagnostics, Zimmer Holdings, Pacira Pharmaceuticals, Geron, and Oculus Innovative Sciences

NEW YORK, December 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Zimmer Holdings, Inc. (NYSE: ZMH), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Geron Corporation (NASDAQ: GERN), and Oculus Innovative Sciences, Inc. (NASDAQ: OCLS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On December 12, 2013, Quest Diagnostics Inc. (Quest Diagnostics) updated its estimates for full-year 2013 revenues and adjusted diluted earnings per share, on a continuing operations basis and before special items. According to the Company, it previously updated its full-year 2013 guidance on October 17, 2013. According to the new update, the Company's expectations for the full-year 2013 indicate the revenues to decline by approximately 3.5% YoY and adjusted earnings per diluted share to be between $3.90 and $3.95. Quest Diagnostics intends to provide guidance for its full-year 2014 in conjunction with its report of Q4 2013 results in January 2014, as is customary for the Company. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ba_DGX

--

Zimmer Holdings, Inc. Research Report

On December 13, 2013 Zimmer Holdings, Inc.'s (Zimmer Holdings) stock rose 0.57%, ending the day at $90.51. Over the previous three trading sessions, shares of Zimmer Holdings declined 1.49%, compared to the Dow Jones industrial average which declined 1.36% during the same period. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9db9_ZMH

--

Pacira Pharmaceuticals Inc. Research Report

On December 13, 2013, Pacira Pharmaceuticals Inc. (Pacira Pharmaceuticals) stock rose 1.81%, ending the day at $50.07. Over the previous three trading sessions, shares of Pacira Pharmaceuticals declined 1.40%, compared to the Nasdaq Composite which declined 1.47% during the same period. The Full Research Report on Pacira Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c0aa_PCRX

--

Geron Corporation Research Report

On December 13, 2013, Geron Corporation's (Geron) stock declined 0.21%, ending the day at $4.77.  Over the previous three trading sessions, shares of Geron declined 7.38%, compared to the Nasdaq Composite which declined 1.47% during the same period. The Full Research Report on Geron Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ca9_GERN

--

Oculus Innovative Sciences, Inc. Research Report

On December 12, 2013, Oculus Innovative Sciences, Inc. (Oculus Innovative Sciences) announced a regulatory approval in Mexico for the Company's new Microcyn-based scar management hydrogel, under the brand name Epicyn. Bruce Thornton, Executive Vice President of Oculus Innovative Sciences, said, "From a corporate perspective, this is just the first of many opportunities for our new scar management hydrogel formulation outside the United States. In addition to the approval by the Mexican Ministry of Health, our Latin American partner, More Pharma, in parallel with the introduction of the new Epicyn™ Scar Hydrogel in the Mexican dermatology market, intends to move forward to secure regulatory approvals, and subsequent product launches, in additional Latin American countries as well. We are exceedingly proud of our teams in both Mexico and the United States for working in tandem to secure respective regulatory approvals." The Company further reported that it previously announced FDA 510(k) regulatory clearance for the Microcyn Scar Management HydroGel. The Full Research Report on Oculus Innovative Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a3ee_OCLS

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner